VALNEVA : gugenheim à l achat ..

Milo13.

13:57

du coup 5€ par action j'imagine... ?

pasjul07

14:40

source ?

gamain2

15:14

Guggenheim lowered its price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on Wednesday while maintaining a Buy rating on the shares. The stock currently trades at $6.03, suggesting substantial upside to the new target, though shares have declined 32% year-to-date.

The firm estimates first-quarter 2026 total revenue of €49.1 million versus the FactSet consensus of €45.1 million. Guggenheim projects Ixiaro sales of €27.9 million compared to consensus of €27.0 million and Dukoral sales of €12.5 million versus consensus of €10.2 million.

The firm estimates €3.3 million in Ixchiq sales driven by ex-U.S. sales following the BLA withdrawal from the U.S. market. Guggenheim projects a total operating income loss of €6.8 million versus consensus of €8.9 million and a diluted EPS loss of €0.05 compared to the Street’s €0.07. An InvestingPro tip notes the company was not profitable over the last twelve months, with analyst consensus remaining at Strong Buy despite near-term challenges. For deeper insights, investors can access Valneva’s comprehensive Pro Research Report, one of 1,400+ available on the platform.

Guggenheim lowered its probability-of-success for the Pfizer-partnered Lyme vaccine PF-07307405 to 65% from 75%. The 95% confidence interval lower bound above 20% was not met in the first pre-specified analysis but was met in the second pre-specified analysis.

The firm noted additional potential catalysts including Shigella vaccine pediatric immunogenicity Phase 2 readout in the first half of 2026 and Shigella vaccine adult controlled human infection model Phase 2 readout in 2026.